



## Original Research Article

## Synthesis Characterisation and *In-Vitro* Anti-microbial Activity of Some Novel 1, 3, 4-Thiadiazole Derivatives

Faruk Alam\*, Biplob Kr. Dey

Dept. of Pharmacy, Assam Down Town University, Panikhaiti, Guwahati, Assam, 781026, India

\* Corresponding Author

Received: 08 January 2015

Revised: 19 January 2015

Accepted: 22 January 2015

### ABSTRACT

The various derivatives of thiadiazole were prepared by the reaction of 2-chloro-*N*-[5-(2-hydroxyphenyl)-1, 3, 4-thiadiazol-2-yl]-acetamide, 2-chloro-*N*-[5-(4-chlorophenyl)-1, 3, 4-thiadiazol-2-yl]-acetamide, 2-chloro-*N*-[5-(2-nitrophenyl)-1,3,4-thiadiazol-2-yl]-acetamide with thiourea /hydrazine hydrate / piperidine in dry alcohol. Elemental analysis, IR, <sup>1</sup>H NMR, mass spectral data confirmed the structure of the newly synthesized compounds. All the derivatives of these moieties were evaluated for *in-vitro* antimicrobial activity. Most of the synthesized compounds showed potent antimicrobial activity at 100 and 50 µg/ml. Compounds showed most significant antibacterial activity against gram positive test organism *B. subtilis* and most significant antifungal activity against test organisms *C. albicans*.

**Keyword:** Synthesis; Aryl carboxylic acid; Thiosemicarbazide; 1, 3, 4-Thiadiazole; Chloroacetylation; Antimicrobial activity

### INTRODUCTION

Microbial diseases are very common all over the world. Currently, used anti-microbial agents are not effective due to development of the resistance against them and therefore, it is an on-going effort for the synthesis of the new antimicrobial agents. Antimicrobial agents reduces or completely block the growth and multiplication of bacteria and are helpful in the treatment of various infectious diseases like meningitis, malaria, Tuberculosis,


pneumonia, AIDS, etc. Heterocyclic Compounds are the cyclic compounds having as ring members atoms of at least two different elements, e.g. quinolone, 1, 2-thiazole, bicycle [3.3.1] tetrasiloxane. Usually they are indicated as counterparts of carbocyclic compounds, which have only ring atoms from the same element. Another classical reference book, the *Encyclopaedia Britannica*, describes a heterocyclic compound, also

called a heterocycle, as: any of a class of organic compounds whose molecules contain one or more rings of atoms with at least one atom (the heteroatom) being an element other than carbon, most frequently oxygen, nitrogen, or sulfur [2]. Although heterocyclic compounds may be inorganic, most contain within the ring structure at least one atom of carbon, and one or more elements such as sulfur, oxygen, or nitrogen [3]. Since non-carbons are usually considered to have replaced carbon atoms, they are called heteroatoms. The structures may consist of either aromatic or non-aromatic rings. There are number of thiadiazoles which contain the nitrogen in different positions such as 1, 2, 3-thiadiazoles [1] and their benzo derivatives [2], the 1, 2, 4-thiadiazoles [3], the 1,3, 4-thiadiazoles [4] and the 1,2,5-thiadiazles (5) and their benzo derivatives [6] etc. The biological activity of the compounds is mainly dependent on their molecular structures [4]. A recent literature survey revealed that the 1, 3, 4-thiadiazole moiety have been widely used by the medicinal chemist in the past to explore its biological activities. The Development of 1, 3, 4-thiadiazole chemistry is linked to the discovery of Phenylhydrazines and hydrazine in the late nineteenth century. It is also well established that various derivatives of 1, 3, 4 - thiadiazoles exhibit broad spectrum of pharmacological properties such as anti-inflammatory [5], antiviral [6], anticonvulsant [7, 8], antifungal [9], anthelmintic [10] CNS depressant [11] and diuretic [12] activities, when properly substituted in the 2-and 5-positions [13]. In the medical field one of the best known drugs having a 1, 3, 4-thiadiazole moiety is acetazolamide, which is a carbonic anhydrase inhibitor launched in 1954. Its indications and usage are many including the treatment of glaucoma, epilepsy and congestive heart failure [14]. Natural and synthetic azetidinone derivatives occupy a central place among medicinally important compounds due to their diverse and interesting antibiotic activities.

## MATERIAL AND METHOD

### Synthetic Procedure

Melting points of all synthesized compounds were determined by open capillary tube method and were uncorrected. Purity of all synthesized compounds was checked by thin layer chromatography technique (0.2 mm thickness of silica gel GF plates) and iodine was used as visualizing agent. IR spectra were recorded on THERMO NICOLET iS10 FT-IR spectrometer using KBr disc method. Elemental analysis was performed using a Euro EA Elemental Analyser. Spectral and Elemental analysis was carried out at Central Analytical Instrument Facility (CAIF), Guwahati biotech park, spectra were recorded on 400-MHz BRUKER spectrometer in dimethylsulfoxide- $d_6$  as solvent and tetramethylsilane (TMS) as internal standard and chemical shift was expressed in  $\delta$  or ppm.



Scheme 1: Schematic representation of 1, 3, 4-thiadiazole derivatives.

## EXPERIMENTAL

### Synthesis of 5-(2-hydroxyphenyl)-2-amino -[1, 3, 4]-thiadiazole **1(a)** <sup>[15, 16]</sup>

A mixture of thiosemicarbazide (0.1mole), 2-hydroxybenzoic acid (0.1mole) and conc. Sulphuric acid (5ml) in 50 ml of ethanol was refluxed for 2-3hour. Reaction was monitored by TLC using mobile phase Chloroform: methanol (4:1). After completion of the reaction the reaction mixture was poured on to crushed ice. The solid separated out was filtered, washed with cold water and recrystallized from ethanol to give colourless crystals, Yield 90 %, m.p.183-186°C.

IR (KBr)  $\nu$ /(cm<sup>-1</sup>): 3514.22 (O-H, st.), 663.92, 688.65 (C-S-C, st.), 3428.26 (NH<sub>2</sub>, N-H, st.), 1616.23 (C=N, st.), 1425.76 (Aryl C=C, st.), 3018.75 (Aryl C-H, st.); <sup>1</sup>H NMR (400MHz, DMSO-*d*6)  $\delta$  6.89-7.20(m, 4H, ArH), 10.32 (s, 1H, OH), 2.60-2.65 (bs, 2H, NH<sub>2</sub>), Mass spectrum m/z: 193 (M<sup>+</sup>).

### Synthesis of 5-(4-chlorophenyl) -2-amino - [1, 3, 4]-thiadiazole (**1b**) <sup>[15, 16]</sup>

A mixture of thiosemicarbazide (0.1mole), 4-chlorobenzoic acid (0.1mole) and conc. sulphuric acid (5ml) in 50 ml of ethanol was refluxed for 2-3hour. Reaction was monitored by TLC using mobile phase Chloroform: methanol (4:1). After completion of the reaction the reaction mixture was poured on to crushed ice. The solid separated out was filtered, washed with cold water and recrystallized from ethanol to give colourless crystals, Yield 79%, m.p.165-167°C ; IR (KBr)  $\nu$ /(cm<sup>-1</sup>): 762.35 (C-Cl, st.), 682.35 (C-S-C, st.), 3447.21 (NH<sub>2</sub>, N-H, st.), 1647.11 (C=N, st.), 1491.70 (C-N, st.), 1425.79 (Aryl C=C, st.), 3025.25 (Aryl C-H, st.); <sup>1</sup>H NMR (400MHz, DMSO-*d*6)  $\delta$  6.95-7.35 (m, 4H, ArH), 2.48 (bs, 2H, NH<sub>2</sub>), Mas spectrum m/z :211(M<sup>+</sup>).

### Synthesis of 5-(2-nitrophenyl) -2-amino - [1, 3, 4]-thiadiazole (**1c**) <sup>[15, 16]</sup>

A mixture of thiosemicarbazide (0.1mole), 2-nitrobenzoic acid (0.1mole) and conc. sulphuric acid (5ml) in 50 ml of ethanol was refluxed for 2-3hour. Reaction was monitored by TLC using mobile phase Chloroform: methanol (4:1). After completion of the reaction the reaction mixture was poured on to crushed ice. The solid separated out was filtered, washed with cold water and recrystallized from ethanol to give light yellow colour crystals, Yield 88%, m.p.225-227°C ; IR (KBr)  $\nu$ /(cm<sup>-1</sup>): 1375.53 , 1545.11, (NO<sub>2</sub>, st.), 687.73 (C-S-C, st.), 34.50.78 (NH<sub>2</sub>, N-H, st.), 1649.95 (C=N, st.), 1416.45 (Aryl C=C, st.), 3087.72 (Aryl C-H, st.); <sup>1</sup>H NMR (400MHz, DMSO-*d*6)  $\delta$  7.30-7.73(m, 4H, ArH), 2.59 (bs, 2H, NH<sub>2</sub>), Mass spectrum m/z: 222 (M<sup>+</sup>).

### Synthesis of 2-Chloro-*N*-[5-(Substituted-phenyl) - [1, 3, 4]-thiadiazol-2-yl]-acetamide **2 (d, e, f)** <sup>[17, 18]</sup>

To the mixture of appropriately substituted compound **I (a, b, c)** (10mmol) in dry benzene (15ml) and 2 ml of dry pyridine, was cooled to 0-5°C. Chloro-acetyl chloride (20mmole) dissolved in dry benzene (10ml) was added drop wise to the solution with constant stirring at room temperature. After complete addition, the reaction mixture was refluxed for about 6-8h. Benzene was removed *in vacuo*. The residue was poured over crushed ice. The precipitate was filtered, washed with water. The crude product was dried and crystallized from 1,4-dioxane to yield compound (**IV d, e, f**); the purity of compounds was analyzed by TLC using benzene: acetone (9:1) as mobile phase. Yield 64.4%, m. p 210 - 212°C.

### 2-(Substituted-amino)-*N*-[5-(Substituted-phenyl)-1, 3, 4-thiadiazol-2-yl]-acetamide (**A1-A9**)

The compound **IV (d, e, f)** 2-Chloro-*N*-[5-(Substituted-phenyl) - [1, 3, 4]-thiadiazol-2-yl]-acetamide (0.01 mol) was taken in about 25 ml of dry alcohol and 0.01 mol of thiourea /hydrazine hydrate / piperidine was added to it and the mixture was heated on water bath for 9 h. The content was

cooled under tap water, filter, dried and recrystallized from alcohol. Purity of the compounds was analyzed by petroleum ether: acetone (9:1) as mobile phase.

The structures of synthesized compounds under investigation were supported by the Physical parameter,  $^1\text{H-NMR}$ , FTIR and MASS spectral measurement. The Physical parameter,  $^1\text{H-NMR}$ , FTIR and Mass spectral data of the synthesized compounds spectra were recorded and assigned in Table 1 and 2.

## ASSESSMENT OF IN-VITRO ANTIMICROBIAL ACTIVITY

### Microbial culture maintenance

The microbial cultures were procured from Dept. of Microbiology, Jadavpur University. The bacterial cultures were cultured in nutrient broth prior to the screening of antimicrobial activity each isolate was checked for its purity and several colonies were emulsified into 50 ml nutrient broth. The inoculated flasks were incubated at  $37^\circ\text{C}$  for 18 h on a rotary shaker at 150 rpm. The bacteria were subcultured on agar slants and maintained at  $4^\circ\text{C}$  until further use. The fungal cultures were grown on Sabouraud's dextrose agar medium containing streptomycin. The plates were incubated in an environmental chamber set at  $25^\circ\text{C}\pm 2^\circ\text{C}$ , 90 % relative humidity (RH), and **Zone of inhibition** [19, 20, 21]

All synthesized compounds were screened for their The *in vitro* antimicrobial activity of all the compounds and standard drugs were assessed against two representatives of gram-positive bacteria viz *Bacillus subtilis* (ATCC11774), *Staphylococcus aureus* (NTCC-6571), two gram-negative bacteria viz *Escherichia coli* (TG14), *Pseudomonas aeruginosa* (ATCC9027) and two fungal strains viz *Aspergillus niger* and *Candida albicans* by cup plate method. The inhibition zone was measured in mm using Amoxycillin, Ofloxacin and Amphotericin B as standards in dimethyl

16:8hrs light: dark regime. An aqueous conidial suspension of  $10^7$  conidia/ml containing 105mg/ml Tween 80 was prepared from 14 day old culture. The conidial viability of the fungi was tested and inoculated with more than 95% germination.

### Evaluation of antimicrobial activity

Evaluation of antimicrobial activities of the test compounds was performed by Cup plate method using muller-Hinton agar medium. The cups of 9 mm diameter were made by scooping out medium with a sterilized cork borer in Petridis which was streaked with the organisms and The solutions of each test compound (0.05 ml, 50  $\mu\text{g}/\text{ml}$  & 0.1 ml, 100  $\mu\text{g}/\text{ml}$ ) were added separately in the cups using a micropipette. The plates were incubated at  $37^\circ\text{C}$  for bacteria and  $26^\circ\text{C}$  for fungi. Following incubation the plates were observed for zones of inhibition. The inhibition zone around the cup as calculated edge to edge zone of confluent growth which is usually corresponds to the sharpest edge of the zone and to be measured diameter in millimeter.

$$\text{Potence} = \text{Antilog}\left[2 + d \left( \frac{(U_2 + U_1) - (S_2 + S_1)}{(U_2 - U_1) + (S_2 - S_1)} \right)\right]$$

sulphoxide (DMSO). DMSO showed no inhibition zone. Each compound and standard drugs were diluted obtaining 1000 $\mu\text{g}/\text{ml}$  concentration, as a stock solution. All the compounds were tested at a concentration of 50 $\mu\text{g}/\text{ml}$  and 100 $\mu\text{g}/\text{ml}$ . Each experiment was repeated twice and the average of the two determinations was recorded. Then the potency of the compounds was calculated by using the following formula as described by Edwin and Marion [22].

In the above equation, 2 is the factor for converting to percent and *d* is the log of the ratio of the

stronger concentration to the weaker. This ratio between dilutions must be the same for both the standard and the compound being assayed.

U2 is zone of inhibition of compound at 100 $\mu\text{g/ml}$ ,

U1 is zone of inhibition of compound at 50 $\mu\text{g/ml}$ ,

S2 is zone of inhibition of standard at 100 $\mu\text{g/ml}$ ,

S1 is zone of inhibition of standard at 50 $\mu\text{g/ml}$ .

The results were reported in Table 3, 4 and 5.

#### **Minimum inhibitory concentration (MIC) [23]:**

The lowest concentration (highest dilution) of compound preventing the appearance of turbidity is considered to be the minimal inhibitory concentration (MIC). At this dilution the compound is known to be bacteriostatic. Bacterial strains were primarily inoculated into Mueller-Hinton agar for overnight growth. A number of colonies were directly suspended in saline solution until the turbidity matched the turbidity of the McFarland standard (approximately  $10^8$  CFU  $\text{ml}^{-1}$ ), i.e., inoculum size for test strain was adjusted to  $10^8$  CFU  $\text{ml}^{-1}$  (Colony Forming Unit per milliliter) per well by comparing the turbidity (turbidimetric method). Similarly, fungi were inoculated on Sabouraud Dextrose broth and the procedures of inoculum standardization were similar. DMSO was used as diluents/vehicle to get desired concentration of the synthesized compounds and standard drugs to test upon standard microbial strains, i.e., the compounds were dissolved in DMSO and the solutions were diluted with a culture medium.

Each compound and standard drugs were diluted obtaining 2000 $\mu\text{g/ml}$  concentration, as a stock solution. By further progressive dilutions with the test medium, the required concentrations were obtained for primary and secondary screening. In primary screening, 0.1ml of culture (bacterial and fungal) was added to the solution of 1000, 500 and 250 $\mu\text{g/ml}$  concentrations of the synthesized compounds were tested.

The active compounds found in this primary screening were further diluted to obtain 200, 100,

62.5, 50, 25, 12.5 and 6.250 $\mu\text{g/ml}$  concentrations for secondary screening to test in a second set of dilution against all microorganisms. Eight MIC tubes were taken and labeled it as number 1-8. Briefly, the control tube (8<sup>th</sup> tube) containing no antibiotic is immediately sub cultured [before inoculation] by spreading a loopful evenly over a quarter of plate of medium suitable for the growth of the tested organism. The tubes are then put for incubation at 37 °C for 24 h for bacteria and 48 h for fungi. Growth or a lack of growth in the tubes containing the antimicrobial agent was determined by comparison with the growth control, indicated by turbidity. The lowest concentration that completely inhibited visible growth of the organism was recorded as the minimal inhibitory concentration (MIC,  $\mu\text{g/ml}$ ), i.e., the amount of growth from the control tube before incubation (which represents the original inoculum) is compared. A set of tubes containing only seeded broth and the solvent controls were maintained under identical conditions so as to make sure that the solvent had no influence on strain growth. The result of this is much affected by the size of the inoculums. The test mixture should contain  $10^8$  CFU  $\text{ml}^{-1}$  organisms. The interpretation of the results was based on Amphotericin B break points for the fungi and also on amoxicillin and ofloxacin for bacterial pathogens. The protocols were summarized in Table 6 as the minimal inhibitory concentration (MIC,  $\mu\text{g/ml}$ ).

## **RESULTS AND DISCUSSION**

### **Chemistry**

Treatment of aryl carboxylic acid in absolute ethanol with thiosemicarbazide afforded the corresponding 2-amino-5(substituted phenyl)-1, 3, 4-thiadiazole **1** (a,b and c). Molecular formula of the compounds (Table 1) derived from elemental analyses data are supported by their molecular weight.

The IR spectrum of **1a** showed characteristic absorption bands at 3428  $\text{cm}^{-1}$  characteristic due to

NH<sub>2</sub> functions in addition to the -OH absorption band at 3514 cm<sup>-1</sup>, C-S-C absorption band at 688 cm<sup>-1</sup>. Its <sup>1</sup>H NMR spectrum revealed the characteristic signal at  $\delta$  10.32 assigned to OH protons, two characteristic signals at  $\delta$  2.60 and 2.65 assigned to NH<sub>2</sub> protons which is exchangeable with D<sub>2</sub>O, confirming the formation of thiadiazole. Also, its mass spectrum showed the molecular ion peak at  $m/z$  193 [M<sup>+</sup>] and the base peak at  $m/z$  94.

The IR spectrum of **1b** showed characteristic absorption bands at 3447 cm<sup>-1</sup> characteristic which is due to NH<sub>2</sub> functions in addition to the C-Cl absorption band at 762 cm<sup>-1</sup>, C-S-C absorption band at 682 cm<sup>-1</sup> and C=C (aromatic) absorption band at 1425 cm<sup>-1</sup>. Its <sup>1</sup>H NMR spectrum revealed the characteristic signal at  $\delta$  2.48 assigned to NH<sub>2</sub> protons which is exchangeable with D<sub>2</sub>O, confirming the formation of thiadiazole. The mass spectrum showed the molecular ion peak at  $m/z$  211 [M<sup>+</sup>] and the base peak at  $m/z$  42.

The IR spectrum of **1c** has exhibited characteristic absorption bands at 3450, 682 and 1416 cm<sup>-1</sup> due to NH<sub>2</sub>, C-S-C and C=C (aromatic) functions respectively. Two characteristic absorption bands at 1375, 1545 cm<sup>-1</sup> which are due to NO<sub>2</sub> function. It was also showed proton signals at:  $\delta$  2.59 (NH<sub>2</sub>) and  $\delta$  7.30-7.73 (Ar-H), respectively. Mass spectrum (**1c**) of the compound exhibited its molecular ion (M<sup>+</sup>) at  $m/z$  222 and the base peak at  $m/z$  206.

To the mixture of compounds **1 (a, b, c)** added solution of chloro-acetyl chloride with constant stirring at room temperature. After complete addition, the reaction mixture was refluxed for about 6-8h. The precipitate was filtered, washed with water to yield compound **2 (a, b, c)**; Yield 64.4%, m. p 210 - 212<sup>o</sup>C.

Compound **2 (a, b, c)** was refluxed for 9h with thiourea /hydrazine hydrate / piperidine in alcohol, to yield **V (A13-A21)**.

The FTIR spectrum of compound **A1, A2 and A3** showed a medium intensity band at 1622, 1612 and 1624 cm<sup>-1</sup> that could correspond with (C=N)

stretching in the vicinity of 1,3,4-thiadiazole ring<sup>1</sup>. In this spectrum there are two other characteristic bands at 3559, 3518, 3521 and 1689, 1655, 1640 cm<sup>-1</sup> due to (O-H) and (C=O) stretching vibrations, respectively. Whereas the compound **A1**, showed two absorption bands at 1122 and 3490 cm<sup>-1</sup> for (C=S) and (NH<sub>2</sub>) stretching vibrations, respectively and in the compound **A2** two absorption bands appeared at 1324 and 2860 cm<sup>-1</sup> for (C-N, st. piperidine) and (CH<sub>2</sub>, st. piperidine) stretching vibrations, respectively. Two characteristic bands were found to be at 3453 and 3088 cm<sup>-1</sup> stretching vibrations, respectively, indicated the presence of (N-H, NH<sub>2</sub>, st.) and (C-H, CH<sub>2</sub>, st.) functions in compound **A3**. The <sup>1</sup>H NMR spectra of these compounds **A1, A2 and A3** showed the signal for the (O-H) group in the  $\delta$  10.12, 10.15 and 9.64 and those for the NH (amide) group at  $\delta$  9.22, 8.69 and 8.85, respectively. The mass spectrum showed the molecular ion peak at  $m/z$  309 [M<sup>+</sup>], 318 [M<sup>+</sup>], 265 [M<sup>+</sup>], respectively, and the base peak at  $m/z$  73, 128 and 127 respectively.

The structures of compounds **A4, A5 and A6** were assigned by IR and <sup>1</sup>H NMR spectroscopic data, which are consistent with the proposed molecular structures. IR spectra of compound **A4, A5 and A6** showed characteristic bands for NH, CH-aliphatic, C-Cl and C=O groups. <sup>1</sup>H-NMR spectrum of compound **A4, A5 and A6** showed signals for CONH at  $\delta$  9.31, 8.85 and 8.81, respectively, for CH<sub>2</sub> at  $\delta$  3.72, 4.27 and 3.55, respectively. The primary amino group in compound **A4 and A6** were depicted by the presence of NH function at  $\delta$  2.60 and 1.99, respectively. The appearance of multiplets at range  $\delta$  1.78-2.69 confirmed the presence of the pyrrolidine ring system in compound **A5**. Mass spectrum of compounds **A4, A5 and A6** showed the molecular ion peak at  $m/z$ : 328 [M+1]<sup>+</sup>, 336 and 282 [M-1]<sup>+</sup>, with a base peak at  $m/z$ : 100, 126 and 157 respectively.

The structures of compounds **A7, A8 and A9** were assigned by IR and <sup>1</sup>H NMR spectroscopic data,

which are consistent with the proposed molecular structures. The primary amino group in compounds **A7** and **A8** was depicted by the presence of NH asymmetric stretch at 3400 and 3434  $\text{cm}^{-1}$ . The IR bending vibration corresponding to C=S of compound **A7** appeared at 1202  $\text{cm}^{-1}$ . The presence of heterocyclic pyrrolidine moiety in compound **A8** was demonstrated by the presence of C-N at 1345  $\text{cm}^{-1}$ . The appearance of C=O stretch in the range of 1626 -1725  $\text{cm}^{-1}$  indicated the formation of secondary amides (**A7** – **A9**) by the reaction of hydrazine/ thiourea/ piperidine with the 2-chloro-*N*-

[5-(2-nitrophenyl)-1,3,4-thiadiazol-2-yl]acetamide. The appearance of singlet at  $\delta$  8.81, 8.95 and 9.10, respectively, corresponds to the proton of CONH in the NMR of all the compounds indicated the presence of secondary amide to the 2nd position of synthesized 1, 3, 4-thiadiazoles moiety (**A7**- **A9**). Mass spectrum of compounds **A7**, **A8** and **A9** were showed the molecular ion peak at  $m/z$ : 338 [ $M^+$ ], 347 [ $M^+$ ] and 294 [ $M^+$ ], respectively, with a base peak at  $m/z$ : 181, 225 and 88 respectively.

**Table 1: Physical parameter of the synthesized compounds**

| Compd.    | Mol. formula   | Mol.Wt | m.p. $^{\circ}\text{C}$ | Yield % | Rf   | Elemental analysis |      |       |       |      |       |
|-----------|--|--------|-------------------------|---------|------|--------------------|------|-------|-------|------|-------|
|           |  |        |                         |         |      | Calculated         |      |       | Found |      |       |
|           |  |        |                         |         |      | C                  | H    | N     | C     | H    | N     |
| <b>1a</b> | $\text{C}_8\text{H}_7\text{N}_3\text{OS}$                  | 193.22 | 185-186                 | 90      | 0.71 | 49.73              | 3.65 | 21.75 | 49.63 | 3.85 | 21.71 |
| <b>1b</b> | $\text{C}_8\text{H}_6\text{ClN}_3\text{S}$                 | 211.67 | 165-167                 | 79      | 0.72 | 45.39              | 2.86 | 19.85 | 45.12 | 2.67 | 19.80 |
| <b>1c</b> | $\text{C}_8\text{H}_6\text{N}_4\text{O}_2\text{S}$         | 222.22 | 225-227                 | 88      | 0.70 | 43.24              | 2.72 | 25.21 | 43.20 | 2.67 | 25.20 |
| <b>2a</b> | $\text{C}_{10}\text{H}_8\text{ClN}_3\text{O}_2\text{S}$    | 269.70 | 210-212                 | 61      | 0.78 | 44.53              | 2.99 | 15.58 | 44.55 | 3.09 | 15.51 |
| <b>2b</b> | $\text{C}_{10}\text{H}_7\text{Cl}_2\text{N}_3\text{OS}$    | 288.15 | 190-193                 | 67      | 0.69 | 41.68              | 2.45 | 14.58 | 40.98 | 2.45 | 14.58 |
| <b>2c</b> | $\text{C}_{10}\text{H}_7\text{ClN}_4\text{O}_3\text{S}$    | 298.70 | 181-183                 | 72      | 0.73 | 40.21              | 2.36 | 18.76 | 39.91 | 2.40 | 19.01 |
| <b>A1</b> | $\text{C}_{11}\text{H}_{11}\text{N}_5\text{O}_2\text{S}_2$ | 309.36 | 169-172                 | 45      | 0.76 | 42.71              | 3.58 | 22.64 | 42.45 | 3.50 | 22.81 |
| <b>A2</b> | $\text{C}_{15}\text{H}_{18}\text{N}_4\text{O}_2\text{S}$   | 318.39 | 173-175                 | 52      | 0.75 | 56.58              | 5.70 | 17.60 | 57.08 | 5.60 | 17.76 |
| <b>A3</b> | $\text{C}_{10}\text{H}_{11}\text{N}_5\text{O}_2\text{S}$   | 265.29 | 145-147                 | 47      | 0.79 | 45.27              | 4.18 | 26.40 | 45.20 | 4.10 | 25.89 |
| <b>A4</b> | $\text{C}_{11}\text{H}_{10}\text{ClN}_5\text{OS}_2$        | 327.81 | 198-200                 | 40      | 0.78 | 40.30              | 3.07 | 21.36 | 40.30 | 3.07 | 21.36 |
| <b>A5</b> | $\text{C}_{15}\text{H}_{17}\text{ClN}_4\text{OS}$          | 336.83 | 135-138                 | 65      | 0.81 | 53.49              | 5.09 | 16.63 | 53.59 | 5.20 | 15.93 |
| <b>A6</b> | $\text{C}_{10}\text{H}_{10}\text{ClN}_5\text{OS}$          | 283.73 | 149-152                 | 79      | 0.72 | 42.33              | 3.55 | 24.68 | 42.63 | 3.78 | 24.99 |
| <b>A7</b> | $\text{C}_{11}\text{H}_{10}\text{N}_6\text{O}_3\text{S}_2$ | 338.36 | 215-217                 | 48      | 0.73 | 39.05              | 2.98 | 24.84 | 39.05 | 2.98 | 24.84 |
| <b>A8</b> | $\text{C}_{15}\text{H}_{17}\text{N}_5\text{O}_3\text{S}$   | 347.39 | 220-222                 | 57      | 0.77 | 51.86              | 4.93 | 20.16 | 51.96 | 4.63 | 20.06 |
| <b>A9</b> | $\text{C}_{10}\text{H}_{10}\text{N}_6\text{O}_3\text{S}$   | 294.28 | 228-230                 | 43      | 0.72 | 40.81              | 3.42 | 28.56 | 40.81 | 3.42 | 28.56 |

### ***In-Vitro* Antimicrobial Activity**

#### ***Antimicrobial Activity (In-Vitro)***

All the compounds synthesized were assayed for their antibacterial activity against two gram positive bacteria (*Staphylococcus aureus*, *Bacillus subtilis*) and two gram negative bacteria (*Escherichia coli*, *Pseudomonas aeruginosa*) and for antifungal activities against *Aspergillus niger*, *Candida albicans* by cup plate method.

Further, their minimum inhibitory concentration (MIC) values against these microorganisms were determined by serial dilution method.

Mullar-Hinton agar plates (37 $^{\circ}\text{C}$ , 24h) and Sabourand dextrose agar plates (26 $^{\circ}\text{C}$ , 72 h) were used for the cultivation of bacteria and fungi, respectively. The results of antibacterial and antifungal activity tests are summarized in Table 1, Table 2, Table 3 and Table 4 of inhibition zones

measurements at conc. 50 and 100 µg/ml and MIC at 200, 100, 62.5, 50, 25, 12.5 and 6.250 µg/ml concentrations for secondary screening to test in a second set of dilution against standard drugs viz. amoxicillin, ofloxacin and amphotericin B for

comparison. Most of the synthesized compounds were found to possess varied degree of bacterial activities as evident from their minimal inhibitory concentration (MIC).

**Table 2: <sup>1</sup>H- NMR, FT-IR and Mass data of compounds (A1-A9)**

| Copd . No. | <sup>1</sup> H-NMR  | IR (KBr) $\nu$ /(cm <sup>-1</sup> )  | Mass (m/z)                              |
|------------|---|--|---|
| A1         | <sup>1</sup> H NMR (400MHz, DMSO- <i>d</i> 6) $\delta$ 6.90-7.52 (m, 4H, ArH); 10.12 (s, 1H, OH); 3.45 (d, 2H, CH <sub>2</sub> ); 6.16 (t, 1H, CH <sub>2</sub> -NH); 9.22 (s, 1H, CONH); 2.87, 2.90 (d, 2H, NH <sub>2</sub> ) | 3559.56 (O-H), 688.51 (C-S-C, st.), 3411.10 (N-H, st.), 1689.70 (C=O, st.), 3119.59 (CH <sub>2</sub> , C-H, st.), 1122.86 (C=S) 1426.53 (Aryl C=C, st.), 3080.72 (Aryl C-H, st.), 3490.53(NH <sub>2</sub> , st.)   | <b>309 (M<sup>+</sup>)</b>              |
| A2         | <sup>1</sup> H NMR (400MHz, DMSO- <i>d</i> 6) $\delta$ 6.88-7.51(m, 4H, ArH);10.15 (s, 1H, OH); 3.12 (s, 2H, CH <sub>2</sub> ); 8.69 (s,1H,CONH); 1.51-1.69 (m, 6H, piperidine ), 2.60, 2.71 (t, 4H, piperidine)              | 3518.34 (O-H), 697.28, 659.15 (C-S-C, st.), 3237.91 (N-H, st.), 1655.19 (C=O, st.), 3040.95 (CH <sub>2</sub> , C-H, st.), 1612.63 (C=N), 1324.90 (C-N,st.piperidine), 2860.33 (CH <sub>2</sub> , C-H, st. piperidine), 1445.93 (Aryl C=C, st.), 2998.01 (Aryl C-H, st.)                                  | <b>318 (M<sup>+</sup>)</b>              |
| A3         | <sup>1</sup> H NMR (400MHz, DMSO- <i>d</i> 6) $\delta$ 6.28-7.94(m, 4H, ArH); 9.64 (s, 1H, OH); 3.91 (d, 2H, CH <sub>2</sub> ); 2.54 (m, 1H, CH <sub>2</sub> -NH); 8.85 (s, 1H, CONH); 2.45 (d, 2H, NH <sub>2</sub> )         | 3521.96 (O-H), 680.47 (C-S-C, st.), 3420.28 (N-H, st.), 1640.57 (C=O, st.), 3088.23 (CH <sub>2</sub> , C-H, st.), 1621.31 (C=N), 1464.43(C-N), 1449.63 (Aryl C=C, st.), 3014.04 (Aryl C-H, st.), 3453.36(NH <sub>2</sub> , st.)  | <b>265 (M<sup>+</sup>)</b>              |
| A4         | <sup>1</sup> H NMR (400MHz, DMSO- <i>d</i> 6) $\delta$ 7.45-7.94(m, 4H, ArH); 3.55 (d, 2H, CH <sub>2</sub> ); 2.81 (m, 1H, CH <sub>2</sub> -NH); 8.83 (s, 1H, CONH); 2.60 (s, 2H, NH <sub>2</sub> )                           | 762.38 (C-Cl), 682.01 (C-S-C, st.), 3410.65 (N-H, st.), 1681.41 (C=O, st.), 2991.53 (CH <sub>2</sub> , C-H, st.), 1591.77 (C=N), 1491.66 (C-N), 1128.66, 1175.69 (C=S), 1424.68 (Aryl C=C, st.), 2836.65 (Aryl C-H, st.), 3289.64 (NH <sub>2</sub> , st.)  | <b>328(M<sup>+</sup>+1<sup>+</sup>)</b> |
| A5         | <sup>1</sup> H NMR (400MHz, DMSO- <i>d</i> 6) $\delta$ 7.33-7.43 (m, 4H, ArH); 3.72 (s, 2H, CH <sub>2</sub> ); 9.31 (s, 1H, CONH); 1.78-1.98 (m, 6H, piperidine), 2.57-2.69 (t, 4H, piperidine)                               | 762.40 (C-Cl), 650.06, 681.85 (C-S-C, st.), 3410.63 (N-H, st.), 1655.19, 1700.08 (C=O, st.), 3083.19 (CH <sub>2</sub> , C-H, st.), 1593.13 (C=N), 1491.75(C-N), 1423.33 (Aryl C=C, st.), 2991.53 (Aryl C-H, st.)   | <b>336 (M<sup>+</sup>)</b>              |
| A6         | <sup>1</sup> H NMR (400MHz, DMSO- <i>d</i> 6) $\delta$ 7.33-8.33(m, 4H, ArH); 4.27 (d, 2H, CH <sub>2</sub> ); 2.49 (m, 1H, CH <sub>2</sub> -NH); 8.85 (s,1H,CONH); 1.99 (d, 2H, NH <sub>2</sub> )                             | 703.34 (C-Cl), 653.01 (C-S-C, st.), 3310.44 (N-H, st.), 1688.21 (C=O, st.), 3104.36 (CH <sub>2</sub> , C-H, st.), 1624.25 (C=N), 1443.31 (Aryl C=C, st.), 3091.58 (Aryl C-H, st.)  | <b>282 (M<sup>+</sup>1<sup>+</sup>)</b> |
| A7         | <sup>1</sup> H NMR (400MHz, DMSO- <i>d</i> 6) $\delta$ 7.01-8.45 (m, 4H, ArH); 3.55(d, 2H, CH <sub>2</sub> ); 2.49 (t, 1H, CH <sub>2</sub> -NH); 8.81 (s, 1H, CONH); 1.98 (d, 2H, NH <sub>2</sub> )                           | 1345.95,1392.86 (NO <sub>2</sub> ), 670.11 (C-S-C, st.), 3340.70 (N-H, st.), 1632.11,1731.44 (C=O, st.), 2770.99 (CH <sub>2</sub> , C-H, st.), 1650.21 (C=N), 1345.95, 1392.86 (C-N), 1202.56, 1077.95, 1054.39 (C=S), 1441.47 (Aryl C=C, st.), 3039.76 (Aryl C-H, st.), 3400.35 (NH <sub>2</sub> , st.) | <b>338 (M<sup>+</sup>)</b>              |
| A8         | <sup>1</sup> H NMR (400MHz, DMSO- <i>d</i> 6) $\delta$ 7.76-8.15 (m, 4H, ArH); 3.31 (s, 2H, CH <sub>2</sub> ); 8.95 (s, 1H, CONH); 1.59-1.63 (m, 6H, piperidine),   | 1398.11, 1515.18 (NO <sub>2</sub> ), 681.85 (C-S-C, st.), 1725.98 (C=O, st.), 3116.52 (CH <sub>2</sub> , C-H, st.), 1653.50 (C=N), 1490.83 (Aryl C=C, st.), 3055.76  | <b>347(M<sup>+</sup>)</b>               |

|    |  |  |                           |
|----|--|--|---------------------------|
| A9 | 2.51-2.62 (t, 4H, piperidine)<br><sup>1</sup> H NMR (400MHz, DMSO- <i>d</i> <sub>6</sub> ) δ 7.43-7.91 (m, 4H, ArH); 3.68 (d, 2H, CH <sub>2</sub> ); 2.90 (m, 1H, CH <sub>2</sub> -NH); 9.10 (s, 1H, CONH); 2.89 (d, 2H, NH <sub>2</sub> ) | (Aryl C-H, st.).<br>1521.33 (NO <sub>2</sub> ), 650.50 (C-S-C, st.), 3450.05 (N-H, st.), 1626.76 (C=O, st.), 1570.14, 1606.78 (C=N), 1443.31 (Aryl C=C, st.), 3096.47 (Aryl C-H, st.), 3190.43 (CH <sub>2</sub> N-H), 3434.03 (NH <sub>2</sub> , st.). | <b>294(M<sup>+</sup>)</b> |
|----|--|--|---------------------------|

### Zone of Inhibition

The results of antibacterial activity are shown in the Table 1 and Table 2 of inhibition zones measurements at conc.50 µg/ml and 100µg/ml. The investigation of the structure–activity relationship of antibacterial screening revealed that the compounds **A2** and **A5** (30.47, 35.58 and 33.26, 37.49% , respectively), with *o*-hydroxyphenyl and *p*-chloro phenyl substituent at the 5-position of the nucleus were found to be highly active against *Staphylococcus aureus* and *Bacillus subtilis*. But against *Bacillus subtilis* compound **A5** was more potent as compare to *Staphylococcus aureus* due to presence of halogen group.

In addition compound **A8** exhibited good inhibitory activities (42.85%) with electron withdrawing group (eg. nitro) substituted phenyl ring on C5 position of the thiadiazole have exhibited better activity against gram negative bacteria *E. coli*. This finding suggests that the presence of a piperidiny ring at linked to the (C2) 1, 3, 4-thiadiazole moiety promotes

increased biological activity. But it was found that compound **A6** and **A7** were inactive towards *E. coli*. Whereas compounds **A1-A9** showed moderate to poor activities against *P.aeruginosa* as compared to ofloxacin.

The results of antifungal activity are shown in the Table 5 of inhibition zones measurements at conc. 50µg/ml and 100µg/ml. Compound **A5** showed the highest activity (30.45%). Whereas rest of the compounds were exhibited moderate activities, while compound **A3** and **A6** did not show any antifungal activity against *A .niger* as compared to Amphotericin B (Table5). Tested compounds **A2** possess promising antifungal activity (39.17%) but the remaining compounds possess poor activities against *C. albicans*.

Thus, it is concluded from the antimicrobial screening results that the most of 1, 3, 4-thiadiazole derivatives have good antibacterial activity compare to the standard against all bacteria and fungi at a concentration of 100µg/ml.

**Table 3: In vitro antibacterial (gram +ve) activities of the prepared compounds: Zone of inhibition in (mm)**

| Compound | <i>S. aureus</i> |      |      |      | %Potency | <i>B. subtilis</i> |      |      |      | %Potency |
|----------|------------------|------|------|------|----------|--------------------|------|------|------|----------|
|          | U2               | U1   | S2   | S1   |          | U2                 | U1   | S2   | S1   |          |
| A1       | 13               | 12   | 29   | 23   | 26.30    | 10                 | 5    | 27   | 22   | 29.37    |
| A2       | 15               | 14   | 29   | 23   | 30.47    | 12                 | 6    | 27   | 22   | 35.48    |
| A3       | 11               | 10   | 29   | 23   | 22.54    | 11                 | 9    | 27   | 22   | 24.09    |
| A4       | 13               | 11   | 29   | 23   | 28.51    | 12                 | 8    | 27   | 22   | 30.97    |
| A5       | 16               | 15   | 29   | 23   | 33.26    | 12                 | 5    | 27   | 22   | 37.49    |
| A6       | 12               | 11   | 29   | 23   | 24.09    | 11                 | 8    | 27   | 22   | 26.60    |
| A7       | 14               | 13   | 29   | 23   | 27.98    | 10                 | 6    | 27   | 22   | 27.28    |
| A8       | 16               | 16   | 29   | 23   | 29.99    | 11                 | 5    | 27   | 22   | 33.26    |
| A9       | 12               | 12   | 29   | 23   | 21.41    | 9                  | 7    | 27   | 22   | 21.23    |
| DMSO     | ----             | ---- | ---- | ---- | ----     | ----               | ---- | ---- | ---- | ----     |

U2: Zone of inhibition of compound at 100 µg/ml; U1: Zone of inhibition of compound at 50 µg/ml; S2: Zone of inhibition of standard at 100 µg/ml; S1: Zone of inhibition of standard at 50 µg/ml. Zone diameter of growth inhibition: (-----) no inhibition.

**Table 4: In vitro antibacterial (gram -ve) activity of the synthesized compounds : Zone of inhibition in (mm)**

| Compound | <i>E. coli</i> |       |      |      | %Potency | <i>P. aeruginosa</i> |       |      |      | %Potency |
|----------|----------------|-------|------|------|----------|----------------------|-------|------|------|----------|
|          | U2             | U1    | S2   | S1   |          | U2                   | U1    | S2   | S1   |          |
| A1       | 4              | 3     | 17   | 13   | 22.69    | 4                    | 3     | 19   | 14   | 21.54    |
| A2       | 4              | 3     | 17   | 13   | 24.94    | 5                    | 4     | 19   | 14   | 24.94    |
| A3       | -----          | ----- | 17   | 13   | -----    | 3                    | 2     | 19   | 14   | 15.23    |
| A4       | 3              | 2     | 17   | 13   | 18.66    | 4                    | 3     | 19   | 14   | 23.06    |
| A5       | 6              | 5     | 17   | 13   | 24.32    | 5                    | 4     | 19   | 14   | 27.03    |
| A6       | 0              | 0     | 17   | 13   | 0.00     | 3                    | 2     | 19   | 14   | 17.10    |
| A7       | 0              | 0     | 17   | 13   | 0.00     | 4                    | 3     | 19   | 14   | 20.88    |
| A8       | 9              | 7     | 17   | 13   | 42.85    | 5                    | 4     | 19   | 14   | 24.54    |
| A9       | 6              | 5.5   | 17   | 13   | 24.32    | -----                | ----- | 19   | 14   | -----    |
| DMSO     | ----           | ----  | ---- | ---- | ----     | ----                 | ----  | ---- | ---- | ----     |

U2: Zone of inhibition of compound at 100 µg/ml; U1: Zone of inhibition of compound at 50 µg/ml; S2: Zone of inhibition of standard at 100 µg/ml; S1: Zone of inhibition of standard at 50 µg/ml.

Zone diameter of growth inhibition: (-----) no inhibition.

**Table 5: In vitro antifungal activities of the prepared compounds: Zone of inhibition in (mm)**

| Compound | <i>A. niger</i> |      |      |      | %Potency | <i>C. albicans</i> |       |      |      | %Potency |
|----------|-----------------|------|------|------|----------|--------------------|-------|------|------|----------|
|          | U2              | U1   | S2   | S1   |          | U2                 | U1    | S2   | S1   |          |
| A1       | 3               | 3    | 18   | 12   | 24.94    | 5                  | 4.6   | 16   | 11   | 30.97    |
| A2       | 3               | 3    | 18   | 12   | 28.84    | 3.5                | 2.7   | 16   | 11   | 39.17    |
| A3       | 0               | 0    | 18   | 12   | 0.00     | 4.1                | 3.4   | 16   | 11   | 29.17    |
| A4       | 3               | 2    | 18   | 12   | 25.62    | 4.2                | 3.1   | 16   | 11   | 30.90    |
| A5       | 4               | 3    | 18   | 12   | 30.48    | 6                  | 5.3   | 16   | 11   | 36.30    |
| A6       | 0               | 0    | 18   | 12   | 0.00     | 3.1                | 2.3   | 16   | 11   | 27.28    |
| A7       | 3               | 2    | 18   | 12   | 24.54    | 4.1                | 3.4   | 16   | 11   | 30.19    |
| A8       | 3               | 2    | 18   | 12   | 27.98    | 5.4                | 4.1   | 16   | 11   | 36.05    |
| A9       | 3               | 2    | 18   | 12   | 24.80    | -----              | ----- | 16   | 11   | -----    |
| DMSO     | ----            | ---- | ---- | ---- | ----     | ----               | ----  | ---- | ---- | ----     |

U2: Zone of inhibition of compound at 100µg/ml; U1: Zone of inhibition of compound at 50µg/ml; S2: Zone of inhibition of standard at 100µg/ml; S1: Zone of inhibition of standard at 50µg/ml.

Zone diameter of growth inhibition: (-----) no inhibition.

#### Minimum Inhibitory Concentration (MIC)

The examination of the data (Table 6) reveals that most of the compounds showed antibacterial and antifungal activity when compared with standard drugs amoxicillin, ofloxacin and amphotericin B.

Compounds **A5** was found to be active against the employed strain to inhibit the growth of organism in comparisons to amoxicillin against *Staphylococcus aureus* (MIC =200µg/ml) and rest of the compounds were showed moderate to poor activity. In

particularly it was found to be compounds **A2**, **A5** and **A8** possess the significance activity against *B. subtilis* (MIC =500µg/ml). It was revealed that the presence of electron withdrawing group, especially halogen and electron donating group in the phenyl ring linked to the 1, 3, 4-thiadiazole moiety play a vital role to increase the biological activity. Towards Gram-negative strain compounds **A2**, **A5** and **A8** showed significant activity (MIC =500µg/ ml), whereas **2b** was found to be equally potent, to ofloxacin, *Escherichia coli* (MIC= 100 µg/ml). Against fungal pathogen *Aspergillus niger*, compounds **A8** was found to be highly potent (MIC =250µg/ml) whereas rest were found to exhibit comparable activity to amphotericin B towards *Aspergillus niger*. Compounds **A2**, **A5**, **A8** and **A9** were exhibited comparable activity to amphotericin B against *Candida albicans* (MIC=500µg/ml). The

remaining compounds showed moderate to poor activity to inhibit the growth of microbial pathogens and are all less effective than standard drugs. Compounds **A1-A9**, some of them are essentially possess a tertiary alkylamine moiety which might be rapidly converts the “base” into the corresponding water soluble salts with the various mineral acids. Obviously, the basic entity is frequently regarded as the hydrophilic entity of the tested compound. It has been scientifically proved that the onium ions generated by protonation of the tertiary amine function were urgently required in carrying out the binding phenomenon with the receptors. From antimicrobial screening results, it is interesting to note that a minor alteration in the molecular configuration of the investigated compounds may have a pronounced effect on antimicrobial activity.

**Table 6: Antimicrobial activity of the synthesized compounds**

| Compound      | Minimum inhibitory concentration (MIC, µg/mL) |                    |                        |                      |                 |                   |
|---------------|---|--------------------|------------------------|----------------------|-----------------|-------------------|
|               | Gram-positive bacteria                        |                    | Gram-negative bacteria |                      |                 | Fungi             |
|               | <i>S. aureus</i>                              | <i>B. subtilis</i> | <i>E. coli</i>         | <i>P. aeruginosa</i> | <i>A. niger</i> | <i>C. albican</i> |
| A1            | 1000  | 1000               | 1000                   | 1000                 | 1000            | 1000              |
| A2            | 250   | 500                | 500                    | 500                  | 1000            | 500               |
| A3            | 1000  | 1000               | 1000                   | 1000                 | 1000            | 1000              |
| A4            | 1000  | 500                | 1000                   | 1000                 | 1000            | 1000              |
| A5            | 200   | 500                | 500                    | 500                  | 500             | 500               |
| A6            | 1000  | 1000               | 1000                   | 1000                 | 1000            | 1000              |
| A7            | 250   | 1000               | 1000                   | 1000                 | 1000            | 1000              |
| A8            | 500   | 500                | 500                    | 1000                 | 250             | 500               |
| A9            | 1000  | 1000               | 1000                   | 1000                 | 1000            | 500               |
| Amoxicillin   | 50  | 250                | ----                   | ----                 | ----            | ----              |
| AmphotericinB | ----  | ----               | ----                   | ----                 | 250             | 100               |
| Ofloxacin     | ----  | ----               | 100                    | 250                  | ----            | ----              |

## CONCLUSION

The preparation procedures follow in this work offers reduction in the reaction time, operation simplicity, cleaner reaction and easy work-up. Thiadiazoles are mesoionic system, a poly-heteroatomic system containing a five-membered heterocycle associated with a conjugation of p and π

electrons and distinct regions of positive and negative charges leading to highly polarizable derivatives. This distinctive characteristic allows mesoionic compounds to effectively cross-cellular membranes and interacts with biological molecules in unique ways. The good liposolubility of the sulphur atom in the heterocycle might also have a

positive effect on the biological activity and pharmacokinetic properties of thiadiazole-containing compounds. The antimicrobial data given for the compounds allowed us to state that the variation of antimicrobial activity may be associated with the nature of tested microorganisms and also is due to the chemical structure of the tested compounds. Performed SAR observation has showed the importance of electronic environment on antimicrobial activity. The presence of halogens (especially chloro) substituents on the aromatic ring have increased the activity of the compounds compared to those with other substituent which may be due to the presence of the versatile pharmacophore which might increase the lipophilic character of the molecules and thus facilitate the crossing through the biological membrane of the microorganisms and thereby inhibit their growth.

#### ACKNOWLEDGEMENT

The authors are thankful to the Dr. N. Dutta (CMD), Assam down town university, Dr. B. K. Dey (Principal), Assam down town University, for providing laboratory facilities. The authors are also thankful to Dr. M. G Borthakur , Central Analytical Instrument Facility (CAIF), Guwahati Biotech Park, Guwathati, also Dr. A. Azome, JSS college of pharmacy, Ooty, India, for providing spectral data.

#### REFERENCES

1. IUPAC, IUPAC Compendium of Chemical Terminology - the Gold Book heterocyclic compounds 2009: Available at <http://goldbook.iupac.org/H02798.html>.
2. Encyclopaedia Britannica, Encyclopedia Britannica Online. The official website: heterocyclic compound. Available at <http://www.britannica.com>
3. Eicher T and Hauptmann S. The Chemistry of Heterocycles: Structure, reactions, syntheses and applications. Verlag Gmb H, Weinheim: Wiley-V C H; 2003.
4. Elzahany EA, Hegab KH , Khalil SKH and Youssef NS. Synthesis, characterization and biological activity of some transition metal complexes with Schiff bases derived from 2-formylindole, salicylaldehyde, and N-amino rhodanine. Aust J Basic Appl Sci 2008; 2(2): 210-220.
5. Sharma S, Srivatsava VK and Kumar A. Synthesis of some newer indolyl-thiadiazolyl-pyrazolines as potential anti-inflammatory agent. Indian J Chem 2002; 41B: 2647-2654.
6. Pandey VK, Tulsi Z and Tandon M. Synthesis of thiadiazole-s-triazines for their antiviral activity based on QSAR studies. Indian J Chem 2003; 42B: 2583-2588.
7. Archana, Srivastava VK and Kumar A. Synthesis of newer Indolyl thiadiazole and their thiazolidinones and formazans as potential anticonvulsant agents. Indian J Pharm Sci 2003; 65(4): 358-362.
8. Chapleo CB, Myers PL, Smith ACB, Tulloch IF and Waltar DS. Substituted 1, 3, 4-thiadiazole with anticonvulsant activity. J Med Chem 1987; 30: 951- 954.
9. Chu CH, Hui XP, Xu PF, Li ZC and Liao RA. Synthesis and antifungal activities of  $\omega$ -(5-aryl amino-1, 3, 4-thiadiazole-2-thio)- $\omega$ -(1H-1, 2, 4-triazol-1-yl) acetophenones. Indian J Chem 2002; 41B: 2436-2438.
10. Saksena RK, Puri S and Prakash R. Synthesis of 2-(aryloxy methyl)-5-(2'-mercapto acetylamino benzoxazol-2'-yl)-1, 3, 4-thiadiazoles as potential anthelmintic agents. Indian J Heterocyclic Chem 2003; 13: 127-130.
11. Mishra P, Jatav V and Kashaw SK. Some novel 2-methyl-3-(1' 3' 4'-thiadiazolyl)-4-(3H) quinazolinones with anticonvulsant and CNS depressant activity. J Indian Chem Soc 2006; 83: 1165-1170.

12. Jain SK and Mishra P. Preparation and evaluation of 1, 3, 4-thiadiazole as diuretic agents. *Indian J Chem* 2004; 43B: 184-188.
13. Mohsen A, Omar ME and Abouj wafa OM. Synthesis and *in-vitro* antimicrobial and antifungal properties of some novel 1,3,4-thiadiazole and *s*- Triazolo [3,4-b] [1,3,4]-thiadiazole derivatives. *Indian J Heterocyclic Chem* 1986; 23: 1339-1341.
14. Wei TB , Liu H , Hu JH, Li ML, Xu WX , Yang LZ and Zhang YM. Microwave promoted efficient synthesis of 2, 5 disubstituted 1,3,4- thiadiazole. *Indian J Chem* 2006; 45B: 2754-2756.
15. Arun KP, Nag VL and Panda CS. Studies on the synthesis and bioactivity of some thiadiazole derivatives. *Indian J Chem* 1999; 38(B): 998-1001.
16. Furniss BS, Hannaford AJ, Smith PWG and Patchel AR. *Vogel's Textbook of practical Organic Chemistry*. Singapore: Pearson Education Pvt. Ltd; 1996.
17. Mullick P, Khan SA, Verma S and Alam O. Synthesis, characterization and antimicrobial activity of new thiadiazole derivatives. *Bull Korean Chem Soc* 2010; 31(8): 2345-2350.
18. Omprakash G, Anjaneyulu Y, Siva Subramanian N, Ramadevi M, Gupta VRM and Vijayalakshmi G. Synthesis, characterization and anti-microbial screening of novel heterocyclic system containing bridgehead nitrogen atom. *Res J Pharma Bio & Chem Sci* 2011; 2(2): 410-415.
19. Barry AL. The antimicrobial susceptibility test: Principle & Practices. *Biol Abstr* 1976; 64: 25783.
20. Antimicrobial-Definition from the Merriam-Webster Online Dictionary. Available at <http://www.merriamwebster.com/dictionary/Antimicrobial>.
21. Prasad YR, Prasoon L, Rao AL, Lakshmi K, Kumar PR and Rao BG. Synthesis and antimicrobial activity of some new chalcones. *Int J Chem Sci* 2005; 3(4): 685-689.
22. Edwin JD and Marion BS. *The paper-disc agar-plate for the assay of antibiotic substances*. New York: Tuckahoe; 1945.
23. Dastidar SG, Chaudhary A, Annadurai S, Roy S, Mookerjee M and Chakrabarty AN. *In Vitro and In Vivo Antimicrobial Action of Fluphenazine*. *J Chemother* 1995; 7 (3): 201-206.

**Cite this article as:**

Faruk Alam and Biplob Kr. Dey. Synthesis Characterisation and *In-Vitro* Anti-microbial Activity of Some Novel 1, 3, 4-Thiadiazole Derivatives. *J Pharm Chem Biol Sci* 2014; 2(4):235-247